Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594148 | 0.86 | NPC1 (0.33) | L3MBTL1GNAI3GNAI1GNAO1POLB | |
| SCHEMBL24926128 | 0.80 | ALDH1A1 (0.37) | — | |
| SCHEMBL23594107 | 0.80 | KDM4E (0.32) | MEN1KMT2A | |
| SCHEMBL12084811 | 0.80 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL23594364 | 0.79 | KDM4E (0.34) | MEN1KMT2A | |
| SCHEMBL26808456 | 0.79 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL26804407 | 0.78 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL23594657 | 0.78 | ALDH1A1 (0.40) | MEN1KMT2A | |
| SCHEMBL23594624 | 0.78 | ALDH1A1 (0.34) | TDP1POLB | |
| SCHEMBL23594453 | 0.77 | KDM4E (0.36) | MEN1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | L3MBTL1 703/4885MEN1 2766/4885KMT2A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.